Eisenthal A, Ramakrishna V, Skornick Y, Shinitzky M
Institute of Oncology, Elias-Sourasky Medical Center, Ichilov Hospital, Tel Aviv, Israel.
Cancer Immunol Immunother. 1993 May;36(5):300-6. doi: 10.1007/BF01741168.
In the preceding paper we have demonstrated an increase in presentation of both major histocompatibility complex antigens (MHC) and a tumor-associated antigen of the weakly immunogenic B16 melanoma by a straight-forward technique. The method consists in modulating the tumor cell membrane by hydrostatic pressure and simultaneous chemical crosslinking of the cell-surface proteins. In B16-BL6 melanoma, the induced antigenic modulation was found to persist for over 48 h, which permitted the evaluation of the ability of modified B16-BL6 cells to induce immunity against unmodified B16-BL6 cells. In the present study, we have shown that a significant systemic immunity was induced only in mice that were immunized with modified B16-BL6 melanoma cells, whereas immunization with unmodified B16-BL6 cells had only a marginal effect when compared to the results in control sham-immunized mice. The induced immunity was specific since a single immunization affected the growth of B16-BL6 tumors but had no effect on MCA 106, an antigenically unrelated tumor. The addition of interleukin-2 to the immunization regimen had no effect on the antitumor responses induced by the modified B16-BL6 cells. The cell-mediated immunity conferred by immunization with treated B16-BL6 cells was confirmed in experiments in vitro where splenocytes from immunized mice could be sensitized to proliferate by the presence of B16-BL6 cells. In addition, the altered antigenicity of these melanoma cells appeared to correlate with their increased susceptibility to specific effectors. Thus, 51Cr-labeled B16-BL6 target cells, modified by pressure and crosslinking, in comparison to control labeled target cells, were lysed in much greater numbers by effectors such as lymphokine-activated killer cells and allogeneic cytotoxic lymphocytes (anti-H-2b), while such cells remained resistant to lysis by natural killer cells. Our findings indicate that the physical and chemical modifications of the tumor cells that are described here may be considered as a simple yet effective method for the preparation of tumor vaccines, which could be applied in tumor-bearing hosts.
在前一篇论文中,我们通过一种直接的技术证明了主要组织相容性复合体抗原(MHC)和弱免疫原性B16黑色素瘤的一种肿瘤相关抗原的呈递增加。该方法包括通过静水压力调节肿瘤细胞膜,并同时对细胞表面蛋白进行化学交联。在B16-BL6黑色素瘤中,发现诱导的抗原调节持续超过48小时,这使得能够评估经修饰的B16-BL6细胞诱导针对未修饰的B16-BL6细胞的免疫的能力。在本研究中,我们表明,仅在用经修饰的B16-BL6黑色素瘤细胞免疫的小鼠中诱导了显著的全身免疫,而与对照假免疫小鼠的结果相比,用未修饰的B16-BL6细胞免疫只有轻微的效果。诱导的免疫是特异性的,因为单次免疫影响B16-BL6肿瘤的生长,但对抗原无关的肿瘤MCA 106没有影响。在免疫方案中添加白细胞介素-2对经修饰的B16-BL6细胞诱导的抗肿瘤反应没有影响。在用处理过的B16-BL6细胞免疫所赋予的细胞介导免疫在体外实验中得到了证实,在该实验中,来自免疫小鼠的脾细胞可以因B16-BL6细胞的存在而被致敏增殖。此外,这些黑色素瘤细胞抗原性的改变似乎与其对特异性效应细胞敏感性的增加相关。因此,与对照标记的靶细胞相比,经压力和交联修饰的51Cr标记的B16-BL6靶细胞被诸如淋巴因子激活的杀伤细胞和同种异体细胞毒性淋巴细胞(抗-H-2b)等效应细胞裂解的数量要多得多,而这些细胞对自然杀伤细胞的裂解仍具有抗性。我们的发现表明,本文所述的肿瘤细胞的物理和化学修饰可被视为一种简单而有效的制备肿瘤疫苗的方法,可应用于荷瘤宿主。